Dr Reddys

Dr Reddy’s warns of 'huge monetary loss' in plea against FSSAI order on ORS

According to the petition, Dr Reddy’s has around 8.47 lakh units of unsold Rebalanz VITORS across its apple, orange and mango variants, with a total realisable value of Rs 1.39 crore, as of October 15

Reduce Dr Reddys; target of Rs 1200: Emkay Global Financial

Emkay Global Financial recommended reduce rating on Dr Reddys with a target price of Rs 1200 in its research report dated October 26, 2025.

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?

The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.

Gainers & Losers: Top 10 stocks that moved the most on July 24

At close, the Sensex was down 542.47 points or 0.66 percent at 82,184.17, and the Nifty was down 157.80 points or 0.63 percent at 25,062.10. About 1564 shares advanced, 2324 shares declined, and 155 shares were unchanged.

Dr Reddy's Laboratories shares rise 3% after Q1; should you buy, sell or hold?

Dr Reddy's Laboratories share price: The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr Reddy’s Q1 earnings quite in line; focus now shifts to key launches ahead

Q1 may have held steady, but the second half of FY26 will test Dr Reddy’s transition strategy. Without Revlimid, and with US pressure persisting, the Street will now watch execution timelines — not just guidance — on Semaglutide, biosimilars and CDMO to gauge whether growth can re-accelerate.

Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth

Brokerages expect steady revenue growth for Dr Reddy’s in Q1FY26, but caution that US price erosion and product mix could weigh on margins and bottomline.

Morgan Stanley initiates coverage on pharma players, bullish only on Sun Pharma

Morgan Stanley sees earnings growth in the pharma sector moderating in FY25–27, though robust balance sheets could support investments in high-growth areas.

Gainers & Losers: Top 10 stocks that moved the most on June 26

At close, the Sensex was up 1,000.36 points or 1.21 percent at 83,755.87, and the Nifty was up 304.25 points or 1.21 percent at 25,549.00. About 1983 shares advanced, 1855 shares declined, and 151 shares unchanged.

Dr Reddy's shares drop 2% as Citi trims target price; sees 26% downside

Dr Reddy's share price: Citi believes that market expectations for the GLP-1 opportunity in Canada may be too optimistic, based on its latest deep dive into the segment.

Delhi High Court restrains Dr.Reddy’s, OneSource from domestic sale of weight loss drug amid patent dispute

Justice Amit Bansal, presiding over the matter, recorded the defendants’ undertaking that they would not sell the impugned drug in India until the next hearing, scheduled for August 19, 2025. The court also took note of Novo Nordisk’s contention that even the export of an infringing product constitutes patent infringement under Indian law.

Pharma shares sulk on Trump's plan to reduce reliance on foreign-made medicines

The USFDA is expected to submit a report within 180 days of the order, reviewing regulations and guidance on development of domestic pharma manufacturing. The Executive Order also proposes steps to eliminate ' duplicative or unnecessary requirements' in regulations.

Dr Reddy's to introduce Sanofi's novel drug in India

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants

Nifty Pharma settles 2% higher on exclusion from Trump's reciprocal tariffs; Lupin, IPCA Labs up 5%

In recent past, U.S President Trump had signalled at potential tariffs on pharma imports as well, calling for bringing overseas manufacturing back to America.

GV Prasad of Dr Reddy's says 25% tariff on pharma exports could make medicines costlier for US consumers

Prasad said shifting all these products (manufacturing) from worldwide into US is not practical.

Will Trump’s tariffs assail Indian pharma, or can it sail through?

In 2024, India exported drugs worth around $8.73 billion to the US — about 31 percent of its total pharma exports, while the US exported $635.37 million worth of pharmaceuticals to India.

Sell Dr Reddys; target of Rs 1150: Emkay Global Financial

Emkay Global Financial is bearish on Dr Reddys recommended sell rating on the stock with a target price of Rs 1150 in its research report dated January 24, 2025.

Q3 Results 2025 Highlights: Adani Green Energy sees profit surge while Mankind Pharma posts revenue growth amid profit decline

Earlier yesterday, HDFC Bank, Hindustan Unilever (HUL), Bharat Petroleum (BPCL), HUDCO, Polycab India, Tata Communications and Heritage Foods announced their Q3 results.

Gainers & Losers: 10 stocks that moved the most on December 20

With today's fall, the Nifty 50 re-entered the correction territory as it has now fallen over 10 percent from its record high.

Senores IPO: A B2B play in pharma generics

Senores has an interesting business model, focusing on generic product identification and development. For the commercialisation and marketing of those products, it has tied up with large generic players.

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing

Sell Dr Reddy's; target of Rs 1070: Emkay Global Financial